What Is NAD+?
NAD+, or nicotinamide adenine dinucleotide, is a coenzyme found in all living cells. Structurally, it is a dinucleotide: two nucleotides — one bearing an adenine base, the other a nicotinamide base — joined through a pair of phosphate groups. It is not a peptide; it belongs to the pyridine nucleotide family and functions as one of the most fundamental cofactors in cellular biochemistry. First described in 1906 by Arthur Harden and William Young, NAD+ has since become one of the most extensively studied molecules in metabolism and aging research.
NAD+ exists in two interconvertible forms: the oxidized form (NAD+), which accepts electrons, and the reduced form (NADH), which carries them. A phosphorylated version of this pair, NADP+/NADPH, supports biosynthetic and antioxidant reactions. What makes NAD+ unusual is that it plays two distinct roles at once — it is both a recyclable electron carrier in energy metabolism and a consumable substrate for a family of signaling enzymes that break it down as part of their catalytic cycle.
A central theme in modern research is that tissue NAD+ concentrations decline with age across many species and organs. This decline has been described as a contributing feature of the aging process, which has driven substantial scientific interest in the pathways that synthesize, consume, and regenerate NAD+, and in the precursor molecules that can raise cellular NAD+ levels.
Molecule Profile
Full Name: Nicotinamide adenine dinucleotide (β-NAD+)
Molecular Formula: C21H27N7O14P2
Molecular Weight: 663.43 g/mol
CAS Number: 53-84-9
Classification: Pyridine dinucleotide coenzyme — a redox cofactor and enzyme substrate, not a peptide
Mechanism of Action
NAD+ operates through two broad and complementary roles: as a redox coenzyme that shuttles electrons through energy metabolism, and as a consumed substrate for a set of enzymes that couple NAD+ availability to cellular signaling. The balance between how NAD+ is regenerated and how it is consumed determines its steady-state level in a cell.
Redox Coenzyme in Energy Metabolism
In its best-established role, NAD+ cycles between its oxidized (NAD+) and reduced (NADH) forms to carry electrons through central metabolism. It accepts electrons during glycolysis, the tricarboxylic acid (TCA) cycle, and fatty-acid oxidation, and NADH then delivers those electrons to complex I of the mitochondrial electron transport chain to drive ATP synthesis. In this capacity NAD+ is not consumed but continuously recycled, and the NAD+/NADH ratio serves as a key readout of a cell's metabolic and energetic state.
Substrate for Sirtuins
Sirtuins (SIRT1 through SIRT7) are a family of NAD+-dependent enzymes that remove acyl groups from histones and other regulatory proteins. Each reaction consumes one molecule of NAD+ and releases nicotinamide. Because their activity is strictly dependent on NAD+ availability, sirtuins act as sensors that link the metabolic state of the cell to processes such as gene expression, mitochondrial biogenesis, and stress responses. This NAD+/sirtuin relationship is one of the most heavily studied axes in aging research.
PARPs and DNA Repair
Poly(ADP-ribose) polymerases (PARPs) consume NAD+ to build ADP-ribose polymers on target proteins as part of the cellular response to DNA damage. Because PARP activity draws directly on the NAD+ pool, extensive or chronic DNA damage can substantially deplete NAD+, and research has examined the resulting competition between DNA repair and other NAD+-dependent pathways such as the sirtuins.
CD38 and NAD+ Consumption
CD38 is a major NAD+-consuming enzyme (an NAD+ glycohydrolase) whose expression tends to rise with age and inflammation. Research has implicated increased CD38 activity as a significant driver of the age-related fall in tissue NAD+, and modulation of CD38 has been studied as one route to preserving NAD+ levels in aged tissues.
The Salvage Pathway
Most cellular NAD+ is continuously regenerated through the salvage pathway, which recycles the nicotinamide released by NAD+-consuming enzymes back into NAD+. The enzyme NAMPT catalyzes the rate-limiting step of this pathway, followed by NMNAT. Cells also make NAD+ de novo from the amino acid tryptophan and through the Preiss-Handler pathway from nicotinic acid. The precursors nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) feed into this salvage machinery, which is why they are studied as means of raising NAD+.
Research Overview
NAD+ has been studied across biochemistry, aging research, metabolism, and neuroscience. A large body of recent work focuses on the decline of NAD+ with age and on the biological effects of raising NAD+ through its precursors, some of which have advanced into early human trials.
| Research Area | Key Findings | Study Type |
|---|---|---|
| Age-Related NAD+ Decline | Tissue NAD+ concentrations have been reported to decrease with age across multiple species and organs, correlating with reduced sirtuin activity and declining mitochondrial function | In vivo (rodent) / human tissue |
| Mitochondrial Function | Restoring NAD+ in aged animal models has been associated with improved mitochondrial respiration, exercise capacity, and metabolic flexibility | In vivo (rodent) |
| Metabolic Health | A randomized trial reported that the precursor NMN increased skeletal-muscle insulin sensitivity in prediabetic women; precursor studies in metabolic dysfunction are ongoing | Human clinical (RCT) |
| Precursor Bioavailability | Nicotinamide riboside has been shown to be orally bioavailable and to raise blood NAD+ in healthy adults in placebo-controlled studies | Human clinical |
| Cardiovascular Research | NAD+ precursor supplementation has been examined for effects on vascular function and blood pressure in middle-aged and older adults | Human clinical |
| Neuroscience | NAD+ metabolism has been studied in models of neurodegeneration and axonal preservation, including the SARM1–NMN axis in Wallerian-type axon degeneration | Preclinical |
NAD+ research spans foundational biochemistry through to active human trials of its precursors (NR and NMN). Preclinical evidence that raising NAD+ affects mitochondrial and metabolic function is extensive, and several small human studies show that precursors reliably elevate blood NAD+. However, robust clinical outcome data in humans remains limited and is an area of ongoing investigation. Much of the strongest human data concerns precursors rather than NAD+ administered directly.
Common Areas of Research Interest
Because NAD+ sits at the intersection of energy metabolism and cellular signaling, its research footprint is broad. The following domains have seen the most published investigation.
- Aging & longevity research, The NAD+/sirtuin axis and the decline of NAD+ with age are studied as contributing features of the aging process
- Metabolic research, Insulin sensitivity, mitochondrial capacity, and energy metabolism, particularly in the context of precursor supplementation
- Cardiovascular research, Vascular function, arterial stiffness, and blood pressure in middle-aged and older subjects
- Neuroscience, Neurodegeneration, axonal degeneration, and cognitive aging, including the SARM1/NAD+ pathway
- Mitochondrial biology, Mitochondrial biogenesis and the efficiency of oxidative phosphorylation
- DNA repair & genomic stability, PARP activity and the competition for NAD+ between DNA repair and other pathways
Pharmacokinetics & Metabolism
NAD+ itself is a large, negatively charged dinucleotide, which limits its direct uptake into cells. As a result, much of the pharmacokinetic interest in NAD+ research centers on its smaller precursors and on the intracellular salvage pathway that regenerates it.
Because intact NAD+ crosses cell membranes poorly, cellular NAD+ is maintained predominantly by intracellular synthesis from smaller building blocks — nicotinamide (recycled via NAMPT), nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), nicotinic acid, and the amino acid tryptophan. This is a central reason that much translational NAD+ research evaluates these more readily absorbed precursors rather than NAD+ delivered directly.
NAD+ turnover in cells is rapid, and its steady-state concentration reflects a continual balance between synthesis (through the salvage and de novo pathways) and consumption (by sirtuins, PARPs, and CD38). Shifts in any of these inputs can move the size of the NAD+ pool, which is why both boosting synthesis and limiting consumption are studied as strategies to maintain NAD+.
Comparison to NAD+ Precursors
NAD+ is frequently discussed alongside its biosynthetic precursors, which are studied as more bioavailable ways to raise cellular NAD+. The table below contrasts NAD+ with two of the most researched precursors.
| Feature | NAD+ | NMN | Nicotinamide Riboside (NR) |
|---|---|---|---|
| Molecule Type | Pyridine dinucleotide coenzyme | Mononucleotide precursor | Nucleoside precursor (a form of vitamin B3) |
| Position in Pathway | The end-product coenzyme itself | One enzymatic step from NAD+ (via NMNAT) | Converted to NMN (via NRK), then to NAD+ |
| Cellular Uptake | Limited direct uptake into cells | Studied via transporter and dephosphorylation routes | Readily taken up and salvaged; oral bioavailability shown in humans |
| Primary Research Focus | Redox metabolism, sirtuin/PARP signaling, aging | Metabolic and insulin-sensitivity research | NAD+ repletion and oral bioavailability trials |
Frequently Asked Questions
Sources & References
- Bogan KL, Brenner C. "Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition." Annual Review of Nutrition. 2008;28:115-130. PubMed
- Imai S, Guarente L. "NAD+ and sirtuins in aging and disease." Trends in Cell Biology. 2014;24(8):464-471. PubMed
- Verdin E. "NAD+ in aging, metabolism, and neurodegeneration." Science. 2015;350(6265):1208-1213. PubMed
- Yoshino J, Baur JA, Imai SI. "NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR." Cell Metabolism. 2018;27(3):513-528. PubMed
- Rajman L, Chwalek K, Sinclair DA. "Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence." Cell Metabolism. 2018;27(3):529-547. PubMed
- Katsyuba E, Romani M, Hofer D, Auwerx J. "NAD+ homeostasis in health and disease." Nature Metabolism. 2020;2(1):9-31. PubMed
- Covarrubias AJ, Perrone R, Grozio A, Verdin E. "NAD+ metabolism and its roles in cellular processes during ageing." Nature Reviews Molecular Cell Biology. 2021;22(2):119-141. PubMed
- Trammell SAJ, et al. "Nicotinamide riboside is uniquely and orally bioavailable in mice and humans." Nature Communications. 2016;7:12948. PubMed
- Martens CR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications. 2018;9(1):1286. PubMed
- Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224-1229. PubMed
Explore NAD+
Available for research purposes. Third-party tested for purity and identity.
View NAD+ — $150This product is intended for research and laboratory use only. It is not intended for human consumption.